Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer

✍ Scribed by O. Guérin; P. Formento; C. Lo Nigro; P. Hofman; J. L. Fischel; M. C. Etienne-Grimaldi; M. Merlano; J. M. Ferrero; G. Milano

• Publisher: Springer-Verlag
• Year: 2007
• Tongue: English
• Weight: 421 KB
• Volume: 134
• Category: Article
• ISSN: 1432-1335
• DOI: 10.1007/s00432-007-0247-4